{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:40:08Z","timestamp":1784248808688,"version":"3.55.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Rev and Rep"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Duchenne muscular dystrophy (DMD) is a severe X-linked disorder characterized by dystrophin gene mutations and mitochondrial dysfunction, leading to progressive muscle weakness and premature death of DMD patients. We developed human Dystrophin Expressing Chimeric (DEC) cells, created by the fusion of myoblasts from normal donors and DMD patients, as a foundation for DT-DEC01 therapy for DMD. Our preclinical studies on <jats:italic>mdx<\/jats:italic> mouse models of DMD revealed enhanced dystrophin expression and functional improvements in cardiac, respiratory, and skeletal muscles after systemic intraosseous DEC administration. The current study explored the feasibility of mitochondrial transfer and fusion within the created DEC cells, which is crucial for developing new therapeutic strategies for DMD. Following mitochondrial staining with MitoTracker Deep Red and MitoTracker Green dyes, mitochondrial fusion and transfer was assessed by Flow cytometry (FACS) and confocal microscopy. The PEG-mediated fusion of myoblasts from normal healthy donors (MB<jats:sup>N<\/jats:sup>\/MB<jats:sup>N<\/jats:sup>) and normal and DMD-affected donors (MB<jats:sup>N<\/jats:sup>\/MB<jats:sup>DMD<\/jats:sup>), confirmed the feasibility of myoblast and mitochondrial fusion and transfer. The colocalization of the mitochondrial dyes MitoTracker Deep Red and MitoTracker Green confirmed the mitochondrial chimeric state and the creation of chimeric mitochondria, as well as the transfer of healthy donor mitochondria within the created DEC cells. These findings are unique and significant, introducing the potential of DT-DEC01 therapy to restore mitochondrial function in DMD patients and in other diseases where mitochondrial dysfunction plays a critical role.<\/jats:p>\n                <jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s12015-024-10756-w","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T08:01:56Z","timestamp":1721203316000},"page":"1819-1829","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Chimeric Cell Therapy Transfers Healthy Donor Mitochondria in Duchenne Muscular Dystrophy"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6372-6122","authenticated-orcid":false,"given":"Maria","family":"Siemionow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Bocian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna T","family":"Bozyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ziemiecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Siemionow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"10756_CR1","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3390\/biomedicines11030830","volume":"11","author":"A Heydemann","year":"2023","unstructured":"Heydemann, A., & Siemionow, M. (2023). A brief review of Duchenne muscular dystrophy treatment options, with an emphasis on two novel strategies. Biomedicines, 11, 830. https:\/\/doi.org\/10.3390\/biomedicines11030830","journal-title":"Biomedicines"},{"key":"10756_CR2","doi-asserted-by":"publisher","first-page":"113086","DOI":"10.1016\/j.expneurol.2019.113086","volume":"323","author":"C Sun","year":"2020","unstructured":"Sun, C., Serra, C., Lee, G., & Wagner, K. R. (2020). Stem cell-based therapies for Duchenne muscular dystrophy. Experimental Neurology, 323, 113086. https:\/\/doi.org\/10.1016\/j.expneurol.2019.113086","journal-title":"Experimental Neurology"},{"key":"10756_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.nmd.2006.10.003","volume":"17","author":"D Skuk","year":"2007","unstructured":"Skuk, D., Goulet, M., Roy, B., Piette, V., C\u00f4t\u00e9, C. H., Chapdelaine, P., Hogrel, J. Y., Paradis, M., Bouchard, J. P., Sylvain, M., et al. (2007). First Test of a high-density injection protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: Eighteen months Follow-Up. Neuromuscular Disorders, 17, 38\u201346. https:\/\/doi.org\/10.1016\/j.nmd.2006.10.003","journal-title":"Neuromuscular Disorders"},{"key":"10756_CR4","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/345350a0","volume":"345","author":"SM Hughes","year":"1990","unstructured":"Hughes, S. M., & Blau, H. M. (1990). Migration of myoblasts across Basal Lamina during skeletal muscle development. Nature, 345, 350\u2013353. https:\/\/doi.org\/10.1038\/345350a0","journal-title":"Nature"},{"key":"10756_CR5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1469-7580.2009.01138.x","volume":"215","author":"A Otto","year":"2009","unstructured":"Otto, A., Collins-Hooper, H., & Patel, K. (2009). The origin, molecular regulation and therapeutic potential of myogenic stem cell populations. Journal of Anatomy, 215, 477\u2013497. https:\/\/doi.org\/10.1111\/j.1469-7580.2009.01138.x","journal-title":"Journal of Anatomy"},{"key":"10756_CR6","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/mt.2014.57","volume":"22","author":"D Skuk","year":"2014","unstructured":"Skuk, D., & Tremblay, J. P. (2014). Clarifying misconceptions about myoblast transplantation in Myology. Molecular Therapy, 22, 897\u2013898. https:\/\/doi.org\/10.1038\/mt.2014.57","journal-title":"Molecular Therapy"},{"key":"10756_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ana.410340105","volume":"34","author":"G Karpati","year":"1993","unstructured":"Karpati, G., Ajdukovic, D., Arnold, D., Gledhill, R. B., Guttmann, R., Holland, P., Koch, P. A., Shoubridge, E., Spence, D., & Vanasse, M. (1993). Myoblast transfer in Duchenne muscular dystrophy. Annals of Neurology, 34, 8\u201317. https:\/\/doi.org\/10.1002\/ana.410340105","journal-title":"Annals of Neurology"},{"key":"10756_CR8","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1056\/NEJM199509283331303","volume":"333","author":"JR Mendell","year":"1995","unstructured":"Mendell, J. R., Kissel, J. T., Amato, A. A., King, W., Signore, L., Prior, T. W., Sahenk, Z., Benson, S., McAndrew, P. E., & Rice, R. (1995). Myoblast transfer in the treatment of Duchenne\u2019s muscular dystrophy. New England Journal of Medicine, 333, 832\u2013838. https:\/\/doi.org\/10.1056\/NEJM199509283331303","journal-title":"New England Journal of Medicine"},{"key":"10756_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/096368979300200203","volume":"2","author":"JP Tremblay","year":"1993","unstructured":"Tremblay, J. P., Malouin, F., Roy, R., Huard, J., Bouchard, J. P., Satoh, A., & Richards, C. L. (1993). Results of a Triple Blind Clinical Study of myoblast transplantations without Immunosuppressive Treatment in Young Boys with Duchenne muscular dystrophy. Cell Transplantation, 2, 99\u2013112. https:\/\/doi.org\/10.1177\/096368979300200203","journal-title":"Cell Transplantation"},{"key":"10756_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/0960-8966(94)00070-p","volume":"5","author":"L Morandi","year":"1995","unstructured":"Morandi, L., Bernasconi, P., Gebbia, M., Mora, M., Crosti, F., Mantegazza, R., & Cornelio, F. (1995). Lack of mRNA and Dystrophin expression in DMD patients Three months after myoblast transfer. Neuromuscular Disorders, 5, 291\u2013295. https:\/\/doi.org\/10.1016\/0960-8966(94)00070-p","journal-title":"Neuromuscular Disorders"},{"key":"10756_CR11","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/mus.880150504","volume":"15","author":"J Huard","year":"1992","unstructured":"Huard, J., Bouchard, J. P., Roy, R., Malouin, F., Dansereau, G., Labrecque, C., Albert, N., Richards, C. L., Lemieux, B., & Tremblay, J. P. (1992). Human myoblast transplantation: Preliminary results of 4 cases. Muscle and Nerve, 15, 550\u2013560. https:\/\/doi.org\/10.1002\/mus.880150504","journal-title":"Muscle and Nerve"},{"key":"10756_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.stemcr.2015.07.016","volume":"5","author":"X Xu","year":"2015","unstructured":"Xu, X., Wilschut, K. J., Kouklis, G., Tian, H., Hesse, R., Garland, C., Sbitany, H., Hansen, S., Seth, R., Knott, P. D., et al. (2015). Human Satellite Cell transplantation and regeneration from diverse skeletal muscles. Stem Cell Reports, 5, 419\u2013434. https:\/\/doi.org\/10.1016\/j.stemcr.2015.07.016","journal-title":"Stem Cell Reports"},{"key":"10756_CR13","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.15252\/emmm.201607129","volume":"8","author":"G Cossu","year":"2016","unstructured":"Cossu, G., Previtali, S. C., Napolitano, S., Cicalese, M. P., Tedesco, F. S., Nicastro, F., Noviello, M., Roostalu, U., Natali Sora, M. G., Scarlato, M., et al. (2016). Intra-arterial transplantation of HLA-Matched Donor mesoangioblasts in Duchenne muscular dystrophy. Embo Molecular Medicine, 8, 1470\u20131471. https:\/\/doi.org\/10.15252\/emmm.201607129","journal-title":"Embo Molecular Medicine"},{"key":"10756_CR14","doi-asserted-by":"publisher","unstructured":"Danisovic, L., Culenova, M., & Csobonyeiova, M. (2018). Induced pluripotent stem cells for duchenne muscular dystrophy modeling and therapy. Cells, 7(12), 253. https:\/\/doi.org\/10.3390\/cells7120253","DOI":"10.3390\/cells7120253"},{"key":"10756_CR15","doi-asserted-by":"publisher","unstructured":"Erkut, E., & Yokota, T. (2022). CRISPR therapeutics for Duchenne muscular dystrophy. International Journal of Molecular Sciences, 23(3), 1832. https:\/\/doi.org\/10.3390\/ijms23031832","DOI":"10.3390\/ijms23031832"},{"key":"10756_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s12015-017-9792-7","volume":"14","author":"M Siemionow","year":"2018","unstructured":"Siemionow, M., Cwykiel, J., Heydemann, A., Garcia-Martinez, J., Siemionow, K., & Szilagyi, E. (2018). Creation of Dystrophin expressing chimeric cells of myoblast origin as a novel stem cell based therapy for Duchenne muscular dystrophy. Stem Cell Rev and Rep, 14, 189\u2013199. https:\/\/doi.org\/10.1007\/s12015-017-9792-7","journal-title":"Stem Cell Rev and Rep"},{"key":"10756_CR17","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s12015-018-9807-z","volume":"14","author":"M Siemionow","year":"2018","unstructured":"Siemionow, M., Cwykiel, J., Heydemann, A., Garcia, J., Marchese, E., Siemionow, K., & Szilagyi, E. (2018). Dystrophin expressing chimeric (DEC) human cells provide a potential therapy for Duchenne muscular dystrophy. Stem Cell Rev and Rep, 14, 370\u2013384. https:\/\/doi.org\/10.1007\/s12015-018-9807-z","journal-title":"Stem Cell Rev and Rep"},{"key":"10756_CR18","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s12015-019-09916-0","volume":"15","author":"M Siemionow","year":"2019","unstructured":"Siemionow, M., Malik, M., Langa, P., Cwykiel, J., Brodowska, S., & Heydemann, A. (2019). Cardiac Protection after systemic transplant of Dystrophin expressing chimeric (DEC) cells to the Mdx Mouse Model of Duchenne muscular dystrophy. Stem Cell Rev and Rep, 15, 827\u2013841. https:\/\/doi.org\/10.1007\/s12015-019-09916-0","journal-title":"Stem Cell Rev and Rep"},{"key":"10756_CR19","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/sctm.21-0054","volume":"10","author":"M Siemionow","year":"2021","unstructured":"Siemionow, M., Langa, P., Harasymczuk, M., Cwykiel, J., Sielewicz, M., Smieszek, J., & Heydemann, A. (2021). Human dystrophin expressing chimeric (DEC) Cell Therapy ameliorates Cardiac, Respiratory, and skeletal muscle\u2019s function in Duchenne muscular dystrophy. Stem Cells Translational Medicine, 10, 1406\u20131418. https:\/\/doi.org\/10.1002\/sctm.21-0054","journal-title":"Stem Cells Translational Medicine"},{"key":"10756_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-022-10384-2","author":"M Siemionow","year":"2022","unstructured":"Siemionow, M., Langa, P., Brodowska, S., Kozlowska, K., Zalants, K., Budzynska, K., & Heydemann, A. (2022). Long-term Protective Effect of Human Dystrophin expressing chimeric (DEC) cell therapy on amelioration of function of Cardiac, respiratory and skeletal muscles in Duchenne muscular dystrophy. Stem Cell Rev and Rep. https:\/\/doi.org\/10.1007\/s12015-022-10384-2","journal-title":"Stem Cell Rev and Rep"},{"key":"10756_CR21","doi-asserted-by":"publisher","unstructured":"Siemionow, M., Brodowska, S., Langa, P., Zalants, K., Kozlowska, K., Grau-Kazmierczak, W., & Heydemann, A. (2022). Long-term biodistribution and safety of human dystrophin expressing chimeric cell therapy after systemic-intraosseous administration to Duchenne muscular dystrophy model. Archivum Immunologiae et Therapiae Experimentalis, 70(1), 20. https:\/\/doi.org\/10.1007\/s00005-022-00656-7","DOI":"10.1007\/s00005-022-00656-7"},{"key":"10756_CR22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.5114\/aic.2021.110990","volume":"18","author":"M Malik","year":"2022","unstructured":"Malik, M., Siemionow, M., Cwykiel, J., Heydemann, A., Garcia-Martinez, J., Siemionow, K., & Szilagyi, E. (2022). Intraosseous transplant of Dystrophin expressing chimeric (DEC) cells improves skeletal muscle function in Mdx Mouse Model of Duchenne muscular dystrophy. Postepy Kardiol Interwencyjnej, 18, 399\u2013406. https:\/\/doi.org\/10.5114\/aic.2021.110990","journal-title":"Postepy Kardiol Interwencyjnej"},{"key":"10756_CR23","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3390\/biomedicines12030586","volume":"12","author":"M Siemionow","year":"2024","unstructured":"Siemionow, M., Budzynska, K., Zalants, K., Langa, P., Brodowska, S., Siemionow, K., & Heydemann, A. (2024). Amelioration of Morphological Pathology in Cardiac, Respiratory, and Skeletal Muscles Following Intraosseous Administration of Human Dystrophin Expressing Chimeric (DEC) cells in Duchenne muscular dystrophy model. Biomedicines, 12, 586. https:\/\/doi.org\/10.3390\/biomedicines12030586","journal-title":"Biomedicines"},{"key":"10756_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-023-10530-4","author":"A Heydemann","year":"2023","unstructured":"Heydemann, A., Bieganski, G., Wachowiak, J., Czarnota, J., Niezgoda, A., Siemionow, K., Ziemiecka, A., Sikorska, M. H., Bozyk, K., Tullius, S. G., et al. (2023). Dystrophin expressing chimeric (DEC) cell therapy for Duchenne muscular dystrophy: A first-in-human study with Minimum 6 months Follow-Up. Stem Cell Rev Rep. https:\/\/doi.org\/10.1007\/s12015-023-10530-4","journal-title":"Stem Cell Rev Rep"},{"key":"10756_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-023-10620-3","author":"M Siemionow","year":"2023","unstructured":"Siemionow, M., Biega\u0144ski, G., Niezgoda, A., Wachowiak, J., Czarnota, J., Siemionow, K., Ziemiecka, A., Sikorska, M. H., Bo\u017cyk, K., & Heydemann, A. (2023). Safety and Efficacy of DT-DEC01 Therapy in Duchenne muscular dystrophy patients: A 12 - Month Follow-Up study after systemic Intraosseous Administration. Stem Cell Rev Rep. https:\/\/doi.org\/10.1007\/s12015-023-10620-3","journal-title":"Stem Cell Rev Rep"},{"key":"10756_CR26","doi-asserted-by":"publisher","unstructured":"Niezgoda, A., Biega\u0144ski, G., Wachowiak, J., Czarnota, J., Siemionow, K., Heydemann, A., Ziemiecka, A., Sikorska, M. H., Bo\u017cyk, K., & Siemionow, M. (2023). Assessment of motor unit potentials duration as the biomarker of DT-DEC01 cell therapy efficacy in duchenne muscular dystrophy patients up to 12 months after systemic-intraosseous administration. Archivum Immunolgiae et Therapiae Experimentalis, 71(1), 24. https:\/\/doi.org\/10.1007\/s00005-023-00691-y","DOI":"10.1007\/s00005-023-00691-y"},{"key":"10756_CR27","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.mehy.2015.08.015","volume":"85","author":"CA Timpani","year":"2015","unstructured":"Timpani, C. A., Hayes, A., & Rybalka, E. (2015). Revisiting the Dystrophin-ATP connection: How half a century of Research still implicates mitochondrial dysfunction in Duchenne muscular dystrophy aetiology. Medical Hypotheses, 85, 1021\u20131033. https:\/\/doi.org\/10.1016\/j.mehy.2015.08.015","journal-title":"Medical Hypotheses"},{"key":"10756_CR28","doi-asserted-by":"publisher","unstructured":"Budzinska, M., Zimna, A., & Kurpisz, M. (2021). The role of Mitochondria in Duchenne muscular dystrophy. Journal of Physiology and Pharmacology, 72(2), 157\u2013166. https:\/\/doi.org\/10.26402\/jpp.2021.2.01","DOI":"10.26402\/jpp.2021.2.01"},{"key":"10756_CR29","doi-asserted-by":"publisher","first-page":"10012","DOI":"10.4081\/ejtm.2021.10012","volume":"31","author":"A Vu Hong","year":"2021","unstructured":"Vu Hong, A., Sanson, M., Richard, I., & Israeli, D. A. (2021). Revised model for mitochondrial dysfunction in Duchenne muscular dystrophy. Eur J Transl Myol, 31, 10012. https:\/\/doi.org\/10.4081\/ejtm.2021.10012","journal-title":"Eur J Transl Myol"},{"key":"10756_CR30","doi-asserted-by":"publisher","first-page":"12926","DOI":"10.3390\/ijms232112926","volume":"23","author":"TH Chen","year":"2022","unstructured":"Chen, T. H., Koh, K. Y., Lin, K. M. C., & Chou, C. K. (2022). Mitochondrial dysfunction as an underlying cause of skeletal muscle disorders. International Journal of Molecular Sciences, 23, 12926. https:\/\/doi.org\/10.3390\/ijms232112926","journal-title":"International Journal of Molecular Sciences"},{"key":"10756_CR31","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.bbadis.2016.11.010","volume":"1863","author":"JS Bhatti","year":"2017","unstructured":"Bhatti, J. S., Bhatti, G. K., & Reddy, P. H. (2017). Mitochondrial dysfunction and oxidative stress in metabolic disorders - a step towards Mitochondria based therapeutic strategies. Biochim Biophys Acta Mol Basis Dis, 1863, 1066\u20131077. https:\/\/doi.org\/10.1016\/j.bbadis.2016.11.010","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10756_CR32","doi-asserted-by":"publisher","first-page":"eadi2767","DOI":"10.1126\/sciadv.adi2767","volume":"9","author":"MJ Bround","year":"2023","unstructured":"Bround, M. J., Havens, J. R., York, A. J., Sargent, M. A., Karch, J., & Molkentin, J. D. (2023). ANT-Dependent MPTP underlies necrotic myofiber death in muscular dystrophy. Science Advances, 9, eadi2767. https:\/\/doi.org\/10.1126\/sciadv.adi2767","journal-title":"Science Advances"},{"key":"10756_CR33","doi-asserted-by":"publisher","first-page":"6751","DOI":"10.1038\/s41598-024-57340-3","volume":"14","author":"MJ Bround","year":"2024","unstructured":"Bround, M. J., Abay, E., Huo, J., Havens, J. R., York, A. J., Bers, D. M., & Molkentin, J. D. (2024). MCU-Independent Ca2\u2009+\u2009uptake mediates mitochondrial Ca2\u2009+\u2009overload and necrotic cell death in a mouse model of Duchenne muscular dystrophy. Scientific Reports, 14, 6751. https:\/\/doi.org\/10.1038\/s41598-024-57340-3","journal-title":"Scientific Reports"},{"key":"10756_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/hmg\/11.3.263","volume":"11","author":"JD Porter","year":"2002","unstructured":"Porter, J. D., Khanna, S., Kaminski, H. J., Rao, J. S., Merriam, A. P., Richmonds, C. R., Leahy, P., Li, J., Guo, W., & Andrade, F. H. (2002). A chronic inflammatory response dominates the Skeletal Muscle Molecular Signature in Dystrophin-Deficient Mdx mice. Human Molecular Genetics, 11, 263\u2013272. https:\/\/doi.org\/10.1093\/hmg\/11.3.263","journal-title":"Human Molecular Genetics"},{"key":"10756_CR35","doi-asserted-by":"publisher","first-page":"891972","DOI":"10.1155\/2015\/891972","volume":"2015","author":"ODR Cruz-Guzm\u00e1n","year":"2015","unstructured":"Cruz-Guzm\u00e1n, O. D. R., Rodr\u00edguez-Cruz, M., & Escobar Cedillo, R. E. (2015). Systemic inflammation in Duchenne muscular dystrophy: Association with muscle function and nutritional status. Biomed Research International, 2015, 891972. https:\/\/doi.org\/10.1155\/2015\/891972","journal-title":"Biomed Research International"},{"key":"10756_CR36","unstructured":"Rozwadowska, N., Sikorska, M., Bozyk, K., Jarosinska, K., Cieciuch, A., Brodowska, S., Andrzejczak, M., & Siemionow, M. Optimization of human myoblasts culture under different media conditions for application in the in vitro studies. American Journal of Stem Cells, 11(1), 1\u201311."},{"key":"10756_CR37","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/nprot.2008.142","volume":"3","author":"B Gharaibeh","year":"2008","unstructured":"Gharaibeh, B., Lu, A., Tebbets, J., Zheng, B., Feduska, J., Crisan, M., P\u00e9ault, B., Cummins, J., & Huard, J. (2008). Isolation of a slowly adhering cell fraction containing stem cells from murine skeletal muscle by the Preplate technique. Nature Protocols, 3, 1501\u20131509. https:\/\/doi.org\/10.1038\/nprot.2008.142","journal-title":"Nature Protocols"},{"key":"10756_CR38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/978-1-62703-317-6_5","volume":"976","author":"M Lavasani","year":"2013","unstructured":"Lavasani, M., Lu, A., Thompson, S. D., Robbins, P. D., Huard, J., & Niedernhofer, L. J. (2013). Isolation of muscle-derived Stem\/Progenitor cells based on adhesion characteristics to collagen-coated surfaces. Methods in Molecular Biology, 976, 53\u201365. https:\/\/doi.org\/10.1007\/978-1-62703-317-6_5","journal-title":"Methods in Molecular Biology"},{"key":"10756_CR39","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41598-017-00853-x","volume":"7","author":"R Yu","year":"2017","unstructured":"Yu, R., Liu, T., Jin, S. B., Ning, C., Lendahl, U., Nist\u00e9r, M., & Zhao, J. (2017). MIEF1\/2 function as adaptors to Recruit Drp1 to Mitochondria and regulate the Association of Drp1 with Mff. Scientific Reports, 7, 880. https:\/\/doi.org\/10.1038\/s41598-017-00853-x","journal-title":"Scientific Reports"},{"key":"10756_CR40","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/cyto.a.20896","volume":"77","author":"J Adler","year":"2010","unstructured":"Adler, J., & Parmryd, I. (2010). Quantifying colocalization by correlation: The Pearson correlation coefficient is Superior to the Mander\u2019s overlap coefficient. Cytometry. Part A, 77, 733\u2013742. https:\/\/doi.org\/10.1002\/cyto.a.20896","journal-title":"Cytometry. Part A"},{"key":"10756_CR41","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/j.1600-6143.2008.02241.x","volume":"8","author":"M Siemionow","year":"2008","unstructured":"Siemionow, M., Klimczak, A., Unal, S., Agaoglu, G., & Carnevale, K. (2008). Hematopoietic stem cell engraftment and seeding permits multi-lymphoid chimerism in vascularized bone marrow transplants. American Journal of Transplantation, 8, 1163\u20131176. https:\/\/doi.org\/10.1111\/j.1600-6143.2008.02241.x","journal-title":"American Journal of Transplantation"},{"key":"10756_CR42","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00005-015-0380-8","volume":"64","author":"M Hivelin","year":"2016","unstructured":"Hivelin, M., Klimczak, A., Cwykiel, J., Sonmez, E., Nasir, S., Gatherwright, J., & Siemionow, M. (2016). Immunomodulatory effects of different Cellular therapies of Bone Marrow Origin on Chimerism Induction and Maintenance across MHC Barriers in a Face Allotransplantation Model. Archivum Immunologiae Et Therapiae Experimentalis, 64, 299\u2013310. https:\/\/doi.org\/10.1007\/s00005-015-0380-8","journal-title":"Archivum Immunologiae Et Therapiae Experimentalis"},{"key":"10756_CR43","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","volume":"77","author":"JR Mendell","year":"2020","unstructured":"Mendell, J. R., Sahenk, Z., Lehman, K., Nease, C., Lowes, L. P., Miller, N. F., Iammarino, M. A., Alfano, L. N., Nicholl, A., Al-Zaidy, S., et al. (2020). Assessment of systemic delivery of rAAVrh74.MHCK7.Micro-Dystrophin in Children with Duchenne muscular dystrophy: A Nonrandomized Controlled Trial. JAMA Neurol, 77, 1122\u20131131. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1484","journal-title":"JAMA Neurol"},{"key":"10756_CR44","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3233\/JND-220811","volume":"9","author":"PR Clemens","year":"2022","unstructured":"Clemens, P. R., Rao, V. K., Connolly, A. M., Harper, A. D., Mah, J. K., McDonald, C. M., Smith, E. C., Zaidman, C. M., Nakagawa, T., & CINRG, D. N. H. S. (2022). Long-term functional efficacy and safety of Viltolarsen in patients with Duchenne muscular dystrophy. J Neuromuscul Dis, 9, 493\u2013501. https:\/\/doi.org\/10.3233\/JND-220811","journal-title":"J Neuromuscul Dis"},{"key":"10756_CR45","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1089\/hum.2022.190","volume":"34","author":"JS Chamberlain","year":"2023","unstructured":"Chamberlain, J. S., Robb, M., Braun, S., Brown, K. J., Danos, O., Ganot, A., Gonzalez-Alegre, P., Hunter, N., McDonald, C., Morris, C., et al. (2023). Microdystrophin expression as a surrogate endpoint for Duchenne muscular dystrophy clinical trials. Human Gene Therapy, 34, 404\u2013415. https:\/\/doi.org\/10.1089\/hum.2022.190","journal-title":"Human Gene Therapy"},{"key":"10756_CR46","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3390\/antiox12040782","volume":"12","author":"I San-Mill\u00e1n","year":"2023","unstructured":"San-Mill\u00e1n, I. (2023). The key role of mitochondrial function in Health and Disease. Antioxidants (Basel), 12, 782. https:\/\/doi.org\/10.3390\/antiox12040782","journal-title":"Antioxidants (Basel)"},{"key":"10756_CR47","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/cdd.2016.127","volume":"24","author":"MC Vila","year":"2017","unstructured":"Vila, M. C., Rayavarapu, S., Hogarth, M. W., Van der Meulen, J. H., Horn, A., Defour, A., Takeda, S., Brown, K. J., Hathout, Y., Nagaraju, K., et al. (2017). Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy. Cell Death and Differentiation, 24, 330\u2013342. https:\/\/doi.org\/10.1038\/cdd.2016.127","journal-title":"Cell Death and Differentiation"},{"key":"10756_CR48","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3389\/fphys.2020.00690","volume":"11","author":"TM Moore","year":"2020","unstructured":"Moore, T. M., Lin, A. J., Strumwasser, A. R., Cory, K., Whitney, K., Ho, T., Ho, T., Lee, J. L., Rucker, D. H., Nguyen, C. Q., et al. (2020). Mitochondrial dysfunction is an early consequence of partial or complete dystrophin loss in Mdx mice. Frontiers in Physiology, 11, 690. https:\/\/doi.org\/10.3389\/fphys.2020.00690","journal-title":"Frontiers in Physiology"},{"key":"10756_CR49","doi-asserted-by":"publisher","first-page":"647010","DOI":"10.3389\/fphys.2021.647010","volume":"12","author":"S Mareedu","year":"2021","unstructured":"Mareedu, S., Million, E. D., Duan, D., & Babu, G. J. (2021). Abnormal calcium handling in Duchenne muscular dystrophy: Mechanisms and potential therapies. Frontiers in Physiology, 12, 647010. https:\/\/doi.org\/10.3389\/fphys.2021.647010","journal-title":"Frontiers in Physiology"},{"key":"10756_CR50","doi-asserted-by":"publisher","unstructured":"Dubinin, M. V., Talanov, E. Y., Tenkov, K. S., Starinets, V. S., Mikheeva, I. B., Sharapov, M. G., & Belosludtsev, K. N. (2020). Duchenne muscular dystrophy is associated with the inhibition of calcium uniport in mitochondria and an increased sensitivity of the organelles to the calcium-induced permeability transition. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1866(5), 165674. https:\/\/doi.org\/10.1016\/j.bbadis.2020.165674","DOI":"10.1016\/j.bbadis.2020.165674"},{"key":"10756_CR51","doi-asserted-by":"publisher","first-page":"1183101","DOI":"10.3389\/fphys.2023.1183101","volume":"14","author":"A Bez Batti Angulski","year":"2023","unstructured":"Bez Batti Angulski, A., Hosny, N., Cohen, H., Martin, A. A., Hahn, D., Bauer, J., & Metzger, J. M. (2023). Duchenne muscular dystrophy: Disease mechanism and therapeutic strategies. Frontiers in Physiology, 14, 1183101. https:\/\/doi.org\/10.3389\/fphys.2023.1183101","journal-title":"Frontiers in Physiology"},{"key":"10756_CR52","doi-asserted-by":"publisher","first-page":"148250","DOI":"10.1016\/j.bbabio.2020.148250","volume":"1861","author":"MV Dubinin","year":"2020","unstructured":"Dubinin, M. V., Talanov, E. Y., Tenkov, K. S., Starinets, V. S., Mikheeva, I. B., & Belosludtsev, K. N. (2020). Transport of Ca2\u2009+\u2009and Ca2+-Dependent permeability transition in Heart Mitochondria in the early stages of Duchenne muscular dystrophy. Biochim Biophys Acta Bioenerg, 1861, 148250. https:\/\/doi.org\/10.1016\/j.bbabio.2020.148250","journal-title":"Biochim Biophys Acta Bioenerg"},{"key":"10756_CR53","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/genes8040108","volume":"8","author":"VPA Johnstone","year":"2017","unstructured":"Johnstone, V. P. A., Viola, H. M., & Hool, L. C. (2017). Dystrophic cardiomyopathy\u2014potential role of Calcium in Pathogenesis, Treatment and Novel therapies. Genes (Basel), 8, 108. https:\/\/doi.org\/10.3390\/genes8040108","journal-title":"Genes (Basel)"},{"key":"10756_CR54","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3390\/cells13070574","volume":"13","author":"SR Casati","year":"2024","unstructured":"Casati, S. R., Cervia, D., Roux-Biejat, P., Moscheni, C., Perrotta, C., & De Palma, C. (2024). Mitochondria and reactive oxygen species: The therapeutic balance of Powers for Duchenne muscular dystrophy. Cells, 13, 574. https:\/\/doi.org\/10.3390\/cells13070574","journal-title":"Cells"},{"key":"10756_CR55","doi-asserted-by":"publisher","first-page":"1346441","DOI":"10.3389\/fendo.2023.1346441","volume":"14","author":"R Chen","year":"2023","unstructured":"Chen, R., & Chen, J. (2023). Mitochondrial transfer - a Novel Promising Approach for the treatment of metabolic diseases. Front Endocrinol (Lausanne), 14, 1346441. https:\/\/doi.org\/10.3389\/fendo.2023.1346441","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10756_CR56","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13578-022-00805-7","volume":"12","author":"Z Liu","year":"2022","unstructured":"Liu, Z., Sun, Y., Qi, Z., Cao, L., & Ding, S. (2022). Mitochondrial Transfer\/Transplantation: An Emerging Therapeutic Approach for multiple diseases. Cell Biosci, 12, 66. https:\/\/doi.org\/10.1186\/s13578-022-00805-7","journal-title":"Cell Biosci"},{"key":"10756_CR57","doi-asserted-by":"publisher","first-page":"e202211044","DOI":"10.1083\/jcb.202211044","volume":"222","author":"LF Dong","year":"2023","unstructured":"Dong, L. F., Rohlena, J., Zobalova, R., Nahacka, Z., Rodriguez, A. M., Berridge, M. V., & Neuzil, J. (2023). Mitochondria on the move: Horizontal mitochondrial transfer in Disease and Health. Journal of Cell Biology, 222, e202211044. https:\/\/doi.org\/10.1083\/jcb.202211044","journal-title":"Journal of Cell Biology"},{"key":"10756_CR58","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/stem.632","volume":"29","author":"A Acquistapace","year":"2011","unstructured":"Acquistapace, A., Bru, T., Lesault, P. F., Figeac, F., Coudert, A. E., le Coz, O., Christov, C., Baudin, X., Auber, F., Yiou, R., et al. (2011). Human mesenchymal stem cells reprogram adult cardiomyocytes toward a progenitor-like state through partial cell Fusion and Mitochondria transfer. Stem Cells, 29, 812\u2013824. https:\/\/doi.org\/10.1002\/stem.632","journal-title":"Stem Cells"},{"key":"10756_CR59","doi-asserted-by":"publisher","first-page":"eaaw7215","DOI":"10.1126\/sciadv.aaw7215","volume":"5","author":"J Gao","year":"2019","unstructured":"Gao, J., Qin, A., Liu, D., Ruan, R., Wang, Q., Yuan, J., Cheng, T. S., Filipovska, A., Papadimitriou, J. M., Dai, K., et al. (2019). Endoplasmic reticulum mediates mitochondrial transfer within the Osteocyte Dendritic Network. Science Advances, 5, eaaw7215. https:\/\/doi.org\/10.1126\/sciadv.aaw7215","journal-title":"Science Advances"},{"key":"10756_CR60","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12951-020-00748-6","volume":"19","author":"P Picone","year":"2021","unstructured":"Picone, P., Porcelli, G., Bavisotto, C. C., Nuzzo, D., Galizzi, G., Biagio, P. L. S., Bulone, D., & Di Carlo, M. (2021). Synaptosomes: New vesicles for neuronal mitochondrial transplantation. J Nanobiotechnology, 19, 6. https:\/\/doi.org\/10.1186\/s12951-020-00748-6","journal-title":"J Nanobiotechnology"},{"key":"10756_CR61","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1242\/bio.024869","volume":"6","author":"KI Wada","year":"2017","unstructured":"Wada, K. I., Hosokawa, K., Ito, Y., & Maeda, M. (2017). Quantitative control of Mitochondria transfer between live single cells using a Microfluidic device. Biol Open, 6, 1960\u20131965. https:\/\/doi.org\/10.1242\/bio.024869","journal-title":"Biol Open"},{"key":"10756_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07340-0","author":"RZ Lin","year":"2024","unstructured":"Lin, R. Z., Im, G. B., Luo, A. C., Zhu, Y., Hong, X., Neumeyer, J., Tang, H. W., Perrimon, N., & Melero-Martin, J. M. (2024). Mitochondrial transfer mediates endothelial cell engraftment through Mitophagy. Nature. https:\/\/doi.org\/10.1038\/s41586-024-07340-0","journal-title":"Nature"},{"key":"10756_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-024-01211-4","author":"KH Kim","year":"2024","unstructured":"Kim, K. H., & Lee, C. B. (2024). Socialized Mitochondria: Mitonuclear Crosstalk in stress. Experimental & Molecular Medicine. https:\/\/doi.org\/10.1038\/s12276-024-01211-4","journal-title":"Experimental & Molecular Medicine"}],"container-title":["Stem Cell Reviews and Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-024-10756-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12015-024-10756-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-024-10756-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T10:17:26Z","timestamp":1727777846000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12015-024-10756-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10756"],"URL":"https:\/\/doi.org\/10.1007\/s12015-024-10756-w","relation":{},"ISSN":["2629-3269","2629-3277"],"issn-type":[{"value":"2629-3269","type":"print"},{"value":"2629-3277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,17]]},"assertion":[{"value":"23 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Bioethics Committee at the Regional Medical Council in Poznan, Poland (approval no. 46\/2019) and Poznan University of Medical Sciences (approval no. 672\/18).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Freely-given, informed consent to participate in the study was obtained from all participants (or their parent or legal guardian in the case of children under 16). The tissues were collected in MedPolonia Hospital (Poznan, Poland) and Poznan University of Medical Sciences. No tissues were obtained from prisoners.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MS is CMO and shareholder of Dystrogen Therapeutics Technology Polska z o.o. the company that holds a license for DT-DEC01 therapy. MS is the inventor on the patent application filed by University of Illinois at Chicago related to chimeric cell therapy for Duchenne muscular dystrophy (WO\/2016\/201182). The author declares a potential conflict of interest. KS is CEO and shareholder of Dystrogen Therapeutics Corp. The author declares a potential conflict of interest. KB, AZ, KJ are Dystrogen Therapeutics Corp. employees.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}